RS50058B - OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE - Google Patents

OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE

Info

Publication number
RS50058B
RS50058B YUP-2005/0413A YU41305A RS50058B RS 50058 B RS50058 B RS 50058B YU 41305 A YU41305 A YU 41305A RS 50058 B RS50058 B RS 50058B
Authority
RS
Serbia
Prior art keywords
oxycodone
controlled release
released
salts
hours
Prior art date
Application number
YUP-2005/0413A
Other languages
Serbian (sr)
Inventor
Benjamin OSHLACK
John Joseph Minogue
Robert Francis Kaiko
Mark Chasin
Original Assignee
Euro-Celtique S.A.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A., filed Critical Euro-Celtique S.A.,
Publication of YU20050413A publication Critical patent/YU20050413A/en
Publication of RS50058B publication Critical patent/RS50058B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Upotreba materijala matrice za kontrolisano oslobađanje koja se sastoji od akrilne smole, za proizvodnju formulacije soli oksikodona sa kontrolisanim oslobađanjem za oralnu primenu kod humanih paci j enata, forrnulacij a se sastoj i od soli oksikodona u količinama koj e su ekvi valentne 10 mg do 160 mg oksikodon hidrohlorida i upotreblj iva je za ublažavanje bola li ravnotežnom stanju posle ponovlj enog davanj a u 12-časovnim intervalima, gde pomenuta formulacija ima in vitro brzinu rastvaranja koja merena Postupkom sa lopaticama (USP Paddle Method) pri 100 oum u 900 ml vodenog pufera (pH između 1.6 i 7.2) na 37oC je između 12.5% i 42.5% (težinskih) soli oksikodona oslobođene posle jednog sata, između 25% i 56% (težinskih) soli oksikodona oslobođene posle 2 sata, između' 45% i 75% (težinskih) soli oksikodona oslobođene posle 4 sata i između 55% i 85% (težinskih) soli oksikodna i oslobođene posle 6 sati. Prijava sadrži još 8 zahteva.Use of a controlled release matrix material consisting of an acrylic resin for the production of a controlled release salt formulation of oral oxycodone for human use, forrnulation also consists of oxycodone salt in amounts equivalent to 10 mg to 160 mg oxycodone hydrochloride and is used to relieve pain or balance after repeated administration at 12-hour intervals, wherein said formulation has an in vitro dissolution rate as measured by the USP Paddle Method at 100 oum in 900 ml of aqueous buffer (pH between 1.6 and 7.2) at 37oC between 12.5% and 42.5% (w / w) of oxycodone salts released after one hour, between 25% and 56% (w / w) oxycodone salts released after 2 hours, between '45% and 75% (w / w) oxycodone salts released after 4 hours and between 55% and 85% (w / w) salts of oxycodone and released after 6 hours. The application contains 8 more requests.

YUP-2005/0413A 1992-11-25 1993-05-21 OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE RS50058B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1014692A 1992-11-25 1992-11-25

Publications (2)

Publication Number Publication Date
YU20050413A YU20050413A (en) 2006-08-17
RS50058B true RS50058B (en) 2008-11-28

Family

ID=37616752

Family Applications (2)

Application Number Title Priority Date Filing Date
YUP-2005/0411A RS50057B (en) 1992-11-25 1993-05-21 OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE
YUP-2005/0413A RS50058B (en) 1992-11-25 1993-05-21 OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
YUP-2005/0411A RS50057B (en) 1992-11-25 1993-05-21 OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE

Country Status (2)

Country Link
ME (6) MEP47808A (en)
RS (2) RS50057B (en)

Also Published As

Publication number Publication date
MEP47708A (en) 2011-02-10
MEP47508A (en) 2011-02-10
MEP47908A (en) 2011-02-10
MEP47808A (en) 2011-02-10
MEP48008A (en) 2011-02-10
RS50057B (en) 2008-11-28
MEP47608A (en) 2011-02-10
YU20050413A (en) 2006-08-17
YU20050411A (en) 2006-08-17

Similar Documents

Publication Publication Date Title
RS50056B (en) OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE
AR042472A1 (en) CONTROLLED RELEASE PREPARATIONS THAT INCLUDE TRAMADOL AND TOPIRAMATO
ATE107857T1 (en) COMPOSITION WITH CONTROLLED RELEASE OF DIHYDROCODEINE.
ATE67933T1 (en) CONTROLLED RELEASE HYDROMORPHONE COMPOSITION.
ATE66813T1 (en) DRUG FORMULATION.
RS52577B (en) Once-a-day oxycodone formulations
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
IL117356A (en) Controlled release matrix and pharmaceutical compositions for oral administration containing it
RU2005115855A (en) COMPOSITION OF TRAMADOL PROLONGED BY RELEASE WITH 24 HOUR ACTION
DK0620731T3 (en) Pharmaceutical composition in the form of a shower and / or decay tablet or instant granule and method of preparation thereof
GEP20053501B (en) Core Tablet for Controlled Release of Gliclazide after Oral Administration
ATE43497T1 (en) PHARMACEUTICAL FORMULATION WITH CONTROLLED ABSORPTION.
HUP9802320A2 (en) Macrolides, procedure of the preparation of macrolides, macrolides containing pharmaceutical products
BR9908910A (en) Transdermal therapeutic system (tts) for transcutaneous administration of oxybutynin and method for its preparation
RS50058B (en) OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE
NO932722L (en) SALTS OF A 4-AMINO-3ACYL-QUINOLINE DERIVATIVE AND THEIR USE AS INHIBATORS FOR GASTRIC ACID SECRETION
YU20050409A (en) Controlled release oxycodone compositions